following a full submission under the end of life and ultra-orphan process
crizotinib (Xalkori®) is accepted for use within NHS Scotland.
Indication under review: First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
In patients with previously untreated advanced ALK-positive NSCLC, crizotinib significantly improved progression-free survival compared with a standard systemic anti-cancer therapy.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of crizotinib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice209KB (PDF)
Medicine details
- Medicine name:
- crizotinib (Xalkori)
- SMC ID:
- 1152/16
- Indication:
- First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 July 2016